Johnson & Johnson
Fair value · base case
Johnson & Johnson trades above base-case fair value as legal and pricing risks weigh.
Price vs. our range
What matters
Select an underlined figure or citation to see its source.
Market implies aggressive growth
Net debt widened sharply
Legal and pricing risks remain
Business and products
Johnson & Johnson sells medical products to wholesalers, hospitals, doctors, and eye care professionals . Competition, research, patents, and regulation drive the business .
- Innovative Medicine sells prescription medicines for cancer, immune, nerve, heart, and infectious diseases to wholesalers, hospitals, and doctors .
- MedTech sells cardiovascular, orthopaedic, surgery, and vision products to hospitals, wholesalers, retailers, and eye care professionals .
Show allShow less
- Competition and the need for new products and protected intellectual property require substantial research investment .
- Government regulation affects product approval, manufacturing, advertising, labeling, and safety reporting .
- Patent challenges and biosimilar launches can reduce sales of key medicines .
Valuation
Valuation ranges
Each bar shows the range a method supports.
· of explicit projections
How we got the discount rate
| Risk-free rate | · Live Treasury |
|---|---|
| Beta | |
| Equity risk premium | |
| WACC |
How sensitive is it?
Fair value per share under different discount rates and long-run growth.
Your model
Build your own view
Adjust the assumptions to see how they change fair value.
The closing price implies 15.2% revenue growth next year.
Show the math
| Starting cash flow | |
|---|---|
| Year-five cash-flow margin | 23.26% |
| Present value of 15 years of cash flow | $242.41B |
| Present value of cash flow after year 15 | $201.83B |
| Net debt | |
| Shares outstanding | |
| Fair value per share | $173 |
Financials
Financial history
Annual figures from SEC filings.
Revenue
Operating margin
Free cash flow (levered, simple)
Diluted EPS
The numbers
Select a figure to see where it came from.
- Net debt
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | |||||
| Operating income | |||||
| Net income | |||||
| R&D | |||||
| Operating cash flow | |||||
| Capital expenditure | |||||
| Share repurchases | |||||
| Free cash flow |
Risks
Key risks
Ranked by impact on fair value. Tap to expand.
HighLitigation could materially reduce fair value.
HighPricing pressure could erode revenue.
HighProduct safety concerns could hurt sales.
ElevatedCompetition could pressure prices and growth.
ElevatedSupply disruptions could reduce sales.
ElevatedIP challenges could curb long-term growth.
Sources
Where this comes from
Numbers are calculated by code from these sources. The AI writes explanations only.
- Legal company name
- JOHNSON & JOHNSON
- SEC SIC
- 2834 · Pharmaceutical Preparations
- Source
- JOHNSON & JOHNSON Form 10-K filed 2026-02-11
- Accession
- 0000200406-26-000016
- Source
- Yahoo Finance (JNJ) — development-only price feed; not for redistribution
- Locator
- 2026-11-17
- Source
- U.S. Treasury Daily Par Yield Curve Rates
- Locator
- 2026-11-17, 10 Yr
- Source
- Aswath Damodaran, NYU Stern — Monthly U.S. implied equity risk premiums (2026-11-01)
- Locator
- Historical ERP / ERP (T12 m with sustainable payout)
- Source
- Aswath Damodaran, NYU Stern — Monthly U.S. implied equity risk premiums (2026-11-01)
- Locator
- Historical ERP / T.Bond Rate
- Source
- Aswath Damodaran, NYU Stern — U.S. industry betas (2026-01-05)
- Locator
- Industry Averages / Drugs (Pharmaceutical) / Unlevered beta corrected for cash
What this report checked
Standard report